# Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

> **NCT01496677** · PHASE1 · COMPLETED · sponsor: **Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 28 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** TR-701 FA 200 mg
- **DRUG:** TR-701 FA 200 mg

## Key facts

- **NCT ID:** NCT01496677
- **Lead sponsor:** Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-17
- **Primary completion:** 2012-02-28
- **Final completion:** 2012-02-28
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496677, "Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01496677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*